These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24114122)

  • 1. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
    Goetz MP; McKean HA; Reid JM; Mandrekar SJ; Tan AD; Kuffel MA; Safgren SL; McGovern RM; Goldberg RM; Grothey AA; McWilliams R; Erlichman C; Ames MM
    Invest New Drugs; 2013 Dec; 31(6):1559-67. PubMed ID: 24114122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
    McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
    Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
    Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
    Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
    Krishnamurthi SS; Brell JM; Hoppel CL; Egorin MJ; Weaver KC; Li X; Ingalls ST; Zuhowski EG; Schluchter MD; Dowlati A; Cooney MM; Gibbons J; Overmoyer BA; Ivy SP; Remick SC
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):441-50. PubMed ID: 18414865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
    McGregor LM; Spunt SL; Furman WL; Stewart CF; Schaiquevich P; Krailo MD; Speights R; Ivy P; Adamson PC; Blaney SM
    Cancer; 2009 Apr; 115(8):1765-75. PubMed ID: 19170226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
    Kweekel DM; Gelderblom H; Van der Straaten T; Antonini NF; Punt CJ; Guchelaar HJ;
    Br J Cancer; 2008 Jul; 99(2):275-82. PubMed ID: 18594531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
    Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F
    J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
    Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
    Zhu J; Li X; Shen Y; Guan Y; Gu W; Lian P; Sheng W; Cai S; Zhang Z
    Radiother Oncol; 2018 Oct; 129(1):143-148. PubMed ID: 29273261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
    Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
    Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
    Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
    Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
    Shin SJ; Ahn JB; Park KS; Lee YJ; Hong YS; Kim TW; Kim HR; Rha SY; Roh JK; Kim DH; Kim C; Chung HC
    Invest New Drugs; 2012 Apr; 30(2):672-80. PubMed ID: 21188464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
    Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
    Toffoli G; Sharma MR; Marangon E; Posocco B; Gray E; Mai Q; Buonadonna A; Polite BN; Miolo G; Tabaro G; Innocenti F
    Clin Cancer Res; 2017 Feb; 23(4):918-924. PubMed ID: 27507617
    [No Abstract]   [Full Text] [Related]  

  • 17. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
    Fornaro L; Masi G; Bursi S; Loupakis F; Vasile E; Antonuzzo A; Chiara S; Pfanner E; Di Paolo A; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):965-9. PubMed ID: 18839174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
    Marcuello E; Páez D; Paré L; Salazar J; Sebio A; del Rio E; Baiget M
    Br J Cancer; 2011 Jun; 105(1):53-7. PubMed ID: 21654688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
    Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
    Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
    Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.